Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Nicholas J. Short, Miguel J Franquiz
Publikováno v:
Biologics: Targets and Therapy. 14:23-34
Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumoma
Publikováno v:
Biologics : Targets & Therapy
Nur Samsu,1 Setyawati Soeharto,2 Muhaimin Rifai,3 Achmad Rudijanto41Department of Internal Medicine, Division of Nephrology and Hypertension, Faculty of Medicine; 2Department of Pharmacology, Faculty of Medicine; 3Department of Biology, Faculty of Ma
Autor:
Chisato Ashida, Akinori Okada, Asuka Inoue, Daisuke Tomita, Yuji Nozaki, Yasuaki Nagare, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura
Publikováno v:
Biologics : Targets & Therapy
Yuji Nozaki, Yasuaki Nagare, Chisato Ashida, Daisuke Tomita, Akinori Okada, Asuka Inoue, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura Department of Hematology and Rheumatology, Kindai University School of Medicine, Osaka, Japan Purpose: We eval
Autor:
Fabrizio Cantini, Maurizio Benucci
Publikováno v:
Biologics : Targets & Therapy
Background The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower
Autor:
Pellegrino Musto, Rosa Lerose, Donatella Telesca, Roberto Guariglia, Maria Rita Milella, Maria Carmen Martorelli
Publikováno v:
Biologics : Targets & Therapy
Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the dura